A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TNG / toxic nodular goiter

[Related PubMed/MEDLINE]
Total Number of Papers: 57
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TNG  (>> Co-occurring Abbreviation)
Long Form:   toxic nodular goiter
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Graves' Disease and Toxic Nodular Goiter, Aggravated by Duration of Hyperthyroidism, Are Associated with Alzheimer's and Vascular Dementia: A Registry-Based Long-Term Follow-Up of Two Large Cohorts. CI, DNPR, GD, ICD-10
2018 Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies. TC
2018 Determinants of Visfatin/NAMPT Serum Concentration and its Leukocyte Expression in Hyperthyroidism. GD
2018 Hyperthyroid patients without Graves' orbitopathy are not at increased risk of developing glaucoma: a nationwide Danish register-based case-control study. GD, HR, OR
2018 No link between season of birth and subsequent development of Graves' disease or toxic nodular goitre: a nationwide Danish register-based study. GD
2017 Is there a group of patients at greater risk for hematoma following thyroidectomy? A systematic review and meta-analysis. ---
2016 Transcriptional activity of TGFbeta1 and its receptors genes in thyroid gland. AITD, GD, NG
2015 Effectiveness of Radioiodine Treatment for Toxic Nodular Goiter. RAIT
10  2015 Hyperthyroidism is associated with work disability and loss of labour market income. A Danish register-based study in singletons and disease-discordant twin pairs. GD, HR
11  2015 Improved quality of life in hyperthyroidism patients after surgery. GD, QOL
12  2015 Long-Term Results of Fixed High-Dose I-131 Treatment for Toxic Nodular Goiter: Higher Euthyroidism Rates in Geriatric Patients. ATD, RAI
13  2015 Organ Dose Estimates for Hyperthyroid Patients Treated with (131)I: An Update of the Thyrotoxicosis Follow-Up Study. GD, ICRP, TTFUS
14  2015 Thyroid cancer in patients with toxic nodular goiter--is the incidence increasing? ---
15  2014 Decreased birth weight, length, and head circumference in children born by women years after treatment for hyperthyroidism. CI, GD, NTG, OR
16  2014 Efficacy of different protocols of radioiodine therapy for treatment of toxic nodular goiter: systematic review and meta-analysis of the literature. ---
17  2013 Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. CI, GD, HR
18  2013 Identification of GPR39 receptor and ghrelin receptor in thyroid tissues in paediatric patients with immune and non-immune thyroid diseases. GD, GHS-R, NTNG
19  2013 Parathyroid gland function after radioiodine ((131)I) therapy for toxic and non-toxic goitre. GD, NTNG
20  2013 The changes in the endothelial function and haemostatic and inflammatory parameters in subclinical and overt hyperthyroidism. GD, IL-12, vWF
21  2013 Toxic nodular goiter and cancer: a compelling case for thyroidectomy. FNA
22  2012 Effect of stressful life events on the initiation of graves' disease. GD, LES
23  2012 The feline thyroid gland: a model for endocrine disruption by polybrominated diphenyl ethers (PBDEs)? FH, PBDE, PBDEs
24  2011 Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men. BMD, DXP, GD
25  2011 The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves' disease and toxic nodular goitre. GD, RAIU
26  2009 Iodine-131 therapy for hyperthyroidism prescribed by endocrinologist - our preliminary experience. GD
27  2007 Clinical significance of metabolic superscan in patients with hyperthyroidism. AP, AT, GD, MSS, PTH
28  2007 Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. GD
29  2007 Prevalence of thyroid antibodies in Nigerian patients. GD, HT, SNTG
30  2007 [Analysis of intracellular proapoptotic (Bax, Bak) and antiapoptotic (Bcl-2, Bcl-XL) proteins expression in thyrocytes from young patients with immune and non-immune thyroid disorders]. GD, NTNG
31  2006 Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. AT, GD, MMI, NTMNG, sCXCL10
32  2006 Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. AT, CA, EU, GD, Hypo, MMI
33  2005 Somatic mutations of the thyroid-stimulating hormone receptor gene in feline hyperthyroidism: parallels with human hyperthyroidism. TSHR
34  2005 Thyroid cancer in hyperthyroidism: incidence rates and value of ultrasound-guided fine-needle aspiration biopsy in this patient group. FTC, GD, PTC, TMNG, US-guided
35  2005 Thyrotropin-stimulated DNA synthesis and thyroglobulin expression in normal and hyperthyroid feline thyrocytes in monolayer culture. HT, NT, Tg
36  2005 [Tobacco smoking in patients with hyperthyroidism]. ETS, GB, GO, TA
37  2005 [Urinary cotinine in patients with hyperthyroidism]. GB, GO
38  2004 High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. BALP, BMD, GD, MMI, OPG, TRAb
39  2004 Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. GD, RAI, TMN
40  2003 [Soluble forms of adhesion molecules sELAM-1 and sICAM-1 in Graves disease and toxic nodular goiter]. ELAM-1, ELISA, GD, GO, ICAM-1
41  2002 E-selectin, L-selectin, ICAM-1 and IL-6 concentrations changes in the serum of patients with hyperthyroidism in the early period of radioiodine I-131 therapy. E-sel, GD, ICAM-1, L-sel, USA
42  2002 Toxic multinodular goiter in the elderly. ---
43  2001 Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre? GD
44  1999 Serum cytokines in thyrotoxicosis. BALP, GD, IL, uDPD
45  1996 Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study. GD
46  1996 Increased incidence of thyrotoxicosis in Malmo during the years 1988-1990 as compared to the years 1970-1974. STA
47  1995 Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs. GD, IL-1 beta, sIL-2R, TT3, TT4
48  1995 Serum laminin in Graves' disease. GD
49  1995 Serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter. GD
50  1991 High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. GD, s-CD8, sIL-2R, TA
51  1988 Enhanced suppression of 1,25(OH)2D3 and intact parathyroid hormone in Graves' disease as compared to toxic nodular goiter. GD, PTH
52  1988 Thyroid carcinoma in thyrotoxic patients treated by surgery. TA, TDG
53  1987 Effects of thyroid stimulating immunoglobulin on function and morphology of xenotransplanted toxic diffuse, toxic nodular and normal thyroid tissue. TDG, TSI
54  1984 Diminished lymphocytic cortisol metabolism-enhancing effect in endogenous thyrotoxicosis. DTG, HP, LCM, LCMEE, PBS
55  1984 HLA antigens in Greek patients with thyrotoxicosis (Graves' disease and toxic nodular goiter). ---
56  1982 Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis. GD, TBII
57  1977 Thyroid uptake of radioactive iodine in hyperthyroidism. ---